What is Niowave?
Niowave stands as a key supplier of critical medical radioisotopes, specializing in the advancement of cancer therapies. The company leverages proprietary accelerator technology and sophisticated radiochemistry to manufacture essential isotopes such as Actinium-225 (Ac-225). By addressing critical supply chain bottlenecks, Niowave ensures a reliable and scalable source of these isotopes, vital for both the clinical development and commercialization of next-generation targeted cancer treatments. Their client base primarily consists of healthcare providers and research organizations dedicated to oncology.
How much funding has Niowave raised?
Niowave has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Niowave?
The recent large-scale, late-stage funding positions Niowave for significant expansion and operational scaling. This strategic investment is expected to accelerate the company's efforts in enhancing its production capacity for Ac-225 and other high-demand medical isotopes. Further capital infusion will likely support the broadening of their client base, deepen research and development into novel radiopharmaceutical applications, and solidify their position as a leader in the medical isotope supply chain, ultimately aiming to improve patient outcomes in cancer care.
See full Niowave company page
